Masaru Konishi

Masaru Konishi

Auto-generated profile, based on publicly available information

Masaru Konishi

Department of Oral and Maxillofacial Radiology, Hiroshima University Hospital, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in Annals of Surgery
Verified
Journal Article
Closed access
JAJunichi Arita
Junichi Arita
KSKentarou Sakamaki
Kentarou Sakamaki
ASAkio Saiura
Akio Saiura
MKMasaru Konishi
Masaru Konishi
YSYoshihiro Sakamoto
Yoshihiro Sakamoto
KSKazuaki Shimada
Kazuaki Shimada
Objective: To assess the clinical impact of a no-drain policy after hepatic resection. Summary of Background Data: Previous randomized controlled trials addressing no-drain policy after hepatic resection seem inconclusive because they did not adopt appropriate study design to validate its true clinical impact. Methods: This unblinded, randomized controlled trial was done at 7 Japanese institutions. Patients undergoing hepatic resection without biliary reconstruction were randomized to either D group or ND group. When the risk of postoperative bile leakage or hemorrhage were considered high, the patients were excluded during the operation. Primary endpoint was the postoperative complication of C-D grade 3 or higher within 90 postoperative days. A noninferiority of ND group to D group was assessed, and if it was confirmed, a superiority was assessed. Results: Between May 2015 and July 2017, a total of 400 patients were finally included in the per-protocol set analysis: 199 patients in D group and 201 patients in ND group. Intraoperatively, 37 patients were excluded from the final enrollment because of high risk of bile leakage or hemorrhage. Postoperative complication rate of C-D grade 3 or higher was 8.0% (16/199) in the D group and 2.5% (5/201) in the ND group. The risk difference was −5.5% (95% confidence interval: −9.9% to −1.2%) and fulfilled the prescribed noninferiority margin of 4%. No postoperative mortality was experienced in both groups. Bile leakage was diagnosed in 8.0% (16/199) of the D group and none in the ND group (P < 0.001). In none of the subgroups classified based on 8 potentially relevant factors, drain placement was favored in terms of C-D grade 3 or higher complication. Conclusions: Drains should not be placed after uncomplicated hepatic resections.

16 February 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
JEJulien Edeline
Julien Edeline
SHSatoshi Hirano
Satoshi Hirano
ABAurelie Bertaut
Aurelie Bertaut
MKMasaru Konishi
Masaru Konishi
MBMeher Benabdelghani
Meher Benabdelghani
TETomoki Ebata
Tomoki Ebata

1 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MIMasafumi Ikeda
Masafumi Ikeda
KNKohei Nakachi
Kohei Nakachi
MKMasaru Konishi
Masaru Konishi
SNShogo Nomura
Shogo Nomura
HKHiroshi Katayama
Hiroshi Katayama
Junji FuruseJunji Furuse
Junji Furuse
382 Background: Capecitabine is usually used for patients with curatively resected biliary tract cancer (BTC) in EU and US, but no clear survival benefit has been shown in phase III trials. S-1, an oral fluoropyrimidine derivative, has shown promising efficacy, with a mild toxicity profile, in patients with advanced BTC. The aim of this trial was to confirm whether adjuvant S-1 therapy might improve the overall survival (OS) in patients with curatively resected BTC. Methods: This open-label, multicenter, randomized phase III trial was conducted in 38 Japanese hospitals. Eligible patients were aged 20 to 80 years old, had undergone R0/R1 resection for histologically confirmed adeno(squamous) carcinoma of the extrahepatic bile duct, gallbladder or ampulla of Vater (T2-4, N0, M0 or T1-4, N1, M0) or the intrahepatic bile duct (T1-4, N0-1, M0) (7th UICC classification), and had an ECOG performance status (PS) of 0 or 1.The calculated sample size was 440 to detect hazard ratio for OS of 0.74 with one-sided alpha of 5% and a power of 80%. Patients in surgery-alone arm received no further anti-cancer treatment, while those in adjuvant S-1 arm received 4 cycles of oral S-1 chemotherapy at the dose of 40 mg/m2 twice daily for 4 weeks, followed by 2 weeks of rest. Primary endpoint was OS, and secondary endpoints were relapse-free survival (RFS), incidence of adverse events, and proportion of treatment completion. Results: A total of 440 patients (surgery-alone, n = 222; adjuvant S-1, n = 218) were enrolled from September 2013 to June 2018. The data cutoff date was June 23, 2021, and the median follow-up duration was 45.4 months. Of all randomized patients, OS was significantly longer with adjuvant S-1 than surgery-alone (hazard ratio [HR] 0.694, 95%CI, 0.514-0.935; one-sided p = 0.008; the 3-year OS, 67.6% [surgery-alone; 95%CI, 61.0-73.3%] and 77.1% [adjuvant S-1; 95%CI, 70.9-82.1%]). Adjuvant S-1 was also better for RFS (HR 0.797 [95%CI, 0.613-1.035], 3-year RFS, 50.9% [surgery-alone; 95%CI, 44.1-57.2%] and 62.4% [adjuvant S-1; 95%CI, 55.6-68.4%]). All preplanned subgroup analyses (PS, age, cancer type, cancer stage, R factor, and serum CA19-9) revealed favorable OS and RFS for adjuvant S-1 arm. The main grade 3-4 adverse events in adjuvant S-1 arm were biliary tract infection (7.2%), diarrhea (2.9%), appetite loss (2.9%), fatigue (2.9%), and the treatment was well-tolerated. Conclusions: Adjuvant S-1 therapy led to significantly longer survival than surgery alone and becomes the standard of care for resected BTC. Clinical trial information: UMIN000011688.

1 March 2006 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
SMShuichi Mitsunaga
Shuichi Mitsunaga
TKTaira Kinoshita
Taira Kinoshita
MKMitsuhiko Kawashima
Mitsuhiko Kawashima
MKMasaru Konishi
Masaru Konishi
TNToshio Nakagohri
Toshio Nakagohri
NGNaoto Gotohda
Naoto Gotohda

17 October 2020 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
HNHiromi Nishi
Hiromi Nishi
STShinya Takahashi
Shinya Takahashi
KOKouji Ohta
Kouji Ohta
MTMegumi Takamoto
Megumi Takamoto
HSHideo Shigeishi
Hideo Shigeishi
HKHidemi Kurihara
Hidemi Kurihara

6 September 2023 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
HNHiromi Nishi
Hiromi Nishi
TOTaiji Obayashi
Taiji Obayashi
TUTsutomu Ueda
Tsutomu Ueda
KOKouji Ohta
Kouji Ohta
HSHideo Shigeishi
Hideo Shigeishi
HKHiroyuki Kawaguchi
Hiroyuki Kawaguchi
Purpose: Several studies have found associations between periodontitis and various types of cancer. Since the site of head and neck cancer (HNC) has contiguity or proximity to the oral cavity, it may be particularly influenced by oral inflammation. This study aimed to determine whether HNC patients have poor oral health as compared to those with other types of cancer. Methods: This study retrospectively examined oral environmental factors including periodontal inflamed surface area (PISA), a new periodontal inflammatory parameter. A total of 1030 cancer patients were divided into the HNC (n = 142) and other cancer (n = 888) groups. Furthermore, the HNC group was divided into high (n = 71) and low (n = 71) PISA subgroups, and independent risk factors affecting a high PISA value were investigated. Results: Multivariate logistic regression analysis showed that number of missing teeth (odds ratio 1.72, 95% CI 1.15–2.56, P < 0.01), PISA (odds ratio 1.06, 95% CI 1.03–1.06, P < 0.05), and oral bacterial count (odds ratio 1.02, 95% CI 1.01–1.03, P < 0.01) were independent factors related to HNC. In addition, multivariate logistic regression analysis indicated that current smoker (odds ratio 7.51, 95% CI 1.63–34.71, P < 0.01) and presence of untreated dental caries (odds ratio 3.33, 95% CI 1.23–9.00, P < 0.05) were independent risk factors affecting high PISA values in HNC patients. Conclusion: HNC patients have higher levels of gingival inflammation and poor oral health as compared to patients with other types of cancer, indicating that prompt oral assessment and an effective oral hygiene management plan are needed at the time of HNC diagnosis.